XT
PTGX icon

XTX Topco’s Protagonist Therapeutics PTGX Stock Holding History

XTX Topco’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$474K Buy
+3,868
New +$404K 0.01% 2509
2025
Q4 		– Sell
-7,260
Closed -$482K – 3696
2025
Q3 		$482K Sell
7,260
-72
-1% -$4.09K 0.03% 1100
2025
Q2 		$405K Sell
7,332
-6,925
-49% -$332K 0.02% 1245
2025
Q1 		$689K Buy
14,257
+7,513
+111% +$315K 0.04% 790
2024
Q4 		$260K Sell
6,744
-8,057
-54% -$351K 0.02% 1338
2024
Q3 		$666K Buy
+14,801
New +$598K 0.05% 628
2023
Q4 		– Sell
-16,139
Closed -$269K – 2022
2023
Q3 		$269K Buy
+16,139
New +$313K 0.05% 807
2023
Q1 		– Sell
-12,942
Closed -$141K – 1587
2022
Q4 		$141K Sell
12,942
-25,882
-67% -$218K 0.03% 938
2022
Q3 		$327K Buy
38,824
+26,201
+208% +$248K 0.08% 459
2022
Q2 		$100K Buy
+12,623
New +$153K 0.04% 645

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

XTX Topco's PTGX Position: Q2 2026 in Review

XTX Topco opened a new position in Protagonist Therapeutics (PTGX) in Q2 2026: 3,868 shares worth $474K. The stake represents 0.01% of the portfolio and ranks #2509 among its holdings. This is a return to the name: XTX Topco previously reported a position in PTGX as recently as Q3 2025.

XTX Topco first reported a position in PTGX in Q2 2022 and has held it in 10 quarters since. The position peaked at $689K in Q1 2025. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • XTX Topco held 3,868 shares of Protagonist Therapeutics worth $474K as of Q2 2026.
  • Protagonist Therapeutics was a new XTX Topco position in Q2 2026.
  • Protagonist Therapeutics made up 0.01% of XTX Topco's portfolio in Q2 2026, its #2509 holding.
  • XTX Topco first reported a position in Protagonist Therapeutics in Q2 2022 and has held it in 10 quarters since.
  • XTX Topco's Protagonist Therapeutics position peaked at $689K in Q1 2025.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.